CCS1477 potently inhibited the growth of androgen receptor (AR) driven prostate cancer cell lines (IC50 = 49–230 nM),112,113 and induced significant growth inhibition in AML and MM cell lines at 100 nM.114,115 In mouse xenograft models of prostate cancer, AML, and MM, CCS1477 induced tumour growth inhibition at 20 mg kg−1 that persisted after dose cessation. Here, AR is linked to Miyoshi myopathy.